novel
coronaviru
current
caus
pandem
show
major
amino
acid
posit
differ
close
relat
sarscov
differenti
conserv
suggest
differ
biolog
behaviour
agreement
novel
cell
cultur
model
reveal
differ
tropism
sarscov
moreov
cellular
receptor
enabl
viru
entri
via
protein
cleavag
level
reliabl
indic
cell
suscept
sarscov
differ
drug
sensit
profil
thu
drug
test
use
reliabl
identifi
therapi
candid
therapeut
concentr
approv
proteas
inhibitor
aprotinin
display
activ
efficaci
aprotinin
remdesivir
current
clinic
investig
enhanc
therapeut
concentr
proton
pump
inhibitor
omeprazol
aprotinin
remdesivir
henc
studi
also
identifi
therapi
candid
readili
test
patient
protein
primarili
papainlik
proteas
supplementari
tabl
base
structur
analysi
propos
dcp
like
result
structur
function
differ
sarscov
protein
could
result
chang
analysi
suggest
remain
dcp
seem
unlik
substanti
effect
protein
structur
function
interest
chang
detect
spike
protein
mediat
coronaviru
entri
host
cell
cui
et
al
chen
et
al
sequenc
ident
sarscov
remain
posit
dcp
residu
tabl
sarscov
entri
depend
cleavag
transmembran
serin
proteas
endosom
cystein
proteas
cathepsin
l
cellular
proteas
residu
critic
cleavag
site
residu
figur
greater
conserv
around
cleavag
site
two
dcp
close
proxim
figur
sarscov
receptor
bind
domain
residu
equival
enrich
dcp
contain
dcp
residu
eleven
sarscov
residu
direct
contact
dcp
figur
supplementari
sarscov
present
interfac
sidechain
point
away
interfac
figur
analysi
complex
highlight
import
role
dcp
abl
form
salt
bridg
figur
yan
et
al
level
cellular
suscept
sarscov
figur
cell
display
lower
level
figur
although
contrast
permiss
sarscov
infect
figur
suggest
factor
addit
cellular
level
determin
cellular
suscept
sarscov
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sarscovinduc
cpe
format
cell
figur
camostat
display
nearli
increas
activ
concentr
inhibit
cpe
format
compar
cov
figur
nafamostat
altern
serin
proteas
inhibitor
approv
pancreat
minakata
et
nafamostat
display
higher
activ
cpe
format
camostat
similar
activ
sarscov
figur
therapeut
plasma
level
compound
describ
reach
hiraku
et
al
cao
et
al
antivir
activ
concentr
moreov
although
compound
inhibit
cpe
format
display
limit
effect
replic
cycl
indic
high
level
doublestrand
rna
nafamostatand
treat
cell
figur
henc
camostat
nafamostat
may
primarili
exert
cytoprotect
effect
cell
inhibit
syncytium
format
cell
lysi
may
inhibit
replic
way
aprotinin
also
effect
cpe
format
kiuml
sarscov
kiuml
figur
addit
contrast
nafamostat
camostat
aprotinin
also
inhibit
doublestrand
rna
format
cell
figur
therapeut
aprotinin
plasma
level
describ
reach
kiuml
administr
kiu
test
addit
antivir
drug
candid
investig
whether
also
differ
drug
sensit
profil
sarscov
antivir
drug
candid
test
two
compound
figur
previou
research
shown
hydroxychloroquin
ammonium
chlorid
interfer
sarscov
replic
lysosomotrop
agent
increas
ph
lysosom
talbot
inhibit
virus
similar
concentr
sarscov
sensit
remdesivir
figur
omeprazol
remdesivir
also
inhibit
format
doublestrand
rna
figur
omeprazol
omeprazol
welltoler
drug
promis
remdesivir
fix
omeprazol
concentr
result
increas
activ
cpe
format
aprotinin
remdesivir
figur
doublestrand
rna
format
figur
henc
combin
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
perform
insilico
analysi
effect
differenti
conserv
amino
acid
posit
dcp
sarscov
protein
viru
protein
structur
function
combin
comparison
wildtyp
sarscov
cell
cultur
analysi
identifi
dcp
repres
amino
acid
posit
differ
sarscov
nearli
residu
encod
sarscov
genom
dcp
residu
like
structur
function
impact
dcp
equal
distribut
protein
dcp
enrich
papainlik
proteas
dcp
present
envelop
e
protein
remain
nonstructur
protein
encod
indic
individu
protein
differ
toler
sequenc
chang
exposur
select
pressur
exert
host
environ
larg
proport
dcp
reflect
differ
clinic
behaviour
sarscov
mortal
associ
sarscov
substanti
higher
associ
wwwwhoint
serin
proteas
inhibitor
camostat
nafamostat
aprotinin
inhibit
sarscov
cpe
format
contrast
aprotinin
camostat
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
nafamostat
exert
limit
activ
doublestrand
rna
format
cell
may
indic
camostat
nafamostat
rather
exert
cytoprotect
effect
prevent
cell
virusinduc
lysi
less
pronounc
antivir
activ
mechan
underli
enhanc
activ
aprotinin
remain
unclear
differ
interfer
addit
proteas
involv
replic
may
respons
notabl
aprotinin
identifi
past
proteas
inhibitor
pronounc
antivir
activ
may
interfer
viral
proteas
addit
cellular
one
conclus
insilico
studi
reveal
substanti
number
differenti
conserv
amino
acid
posit
sarscov
protein
agreement
cell
cultur
experi
identifi
differ
cell
tropism
drug
sensit
profil
two
virus
data
also
show
cellular
level
reliabl
indic
cell
suscept
henc
express
studi
suffici
predict
cell
tropism
differ
drug
sensit
profil
sarscov
close
relat
coronaviru
known
caus
diseas
human
indic
approach
identifi
drug
requir
test
viru
final
probabl
importantli
ongo
pandem
shown
approv
drug
aprotinin
inhibit
infect
clinic
achiev
concentr
efficaci
aprotinin
remdesivir
investig
clinic
trial
enhanc
therapeut
concentr
proton
pump
inhibitor
omeprazol
henc
studi
identifi
novel
candid
therapi
base
approv
drug
readili
test
clinic
set
absorbancebas
quantif
rna
yield
perform
use
genesi
uvvi
spectrophotomet
thermo
scientif
rna
subject
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
onestep
qrtpcr
analysi
use
luna
univers
onestep
rtqpcr
kit
new
england
biolab
realtim
system
touch
thermal
cycler
primer
adapt
target
open
read
frame
rnadepend
rna
polymeras
rdrp
gtg
ara
tgg
tca
tgt
gtg
gcg
g
car
atg
tta
aa
aca
cta
tta
gca
ta
use
per
reaction
standard
curv
creat
use
plasmid
dna
harbour
correspond
amplicon
region
rdrp
target
sequenc
accord
genbank
access
number
condit
three
biolog
replic
use
mean
standard
deviat
calcul
group
immunostain
doublestrand
rna
immunostain
perform
previous
describ
cinatl
et
al
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
acknowledg
author
thank
shinji
makino
utmb
galveston
tx
provis
cell
data
avail
data
provid
manuscript
supplement
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
